RxSight, Inc. (RXST)

Over the past six months, RxSight's stock price has experienced significant fluctuations. Key events impacting the stock include preliminary Q1 2025 revenue and revised 2025 guidance, Q3 2025 financial results, preliminary Q4 and full-year 2025 financial results with a new CFO, Q4 and full-year 2025 results with 2026 guidance, and a securities class action lawsuit filed against the company.

Demand for RxSight's products is influenced by the seasonality of cataract surgeries, with biannual peaks often observed in the spring and autumn months. RxSight anticipates its first quarter to be seasonally weakest, with sales growth expected to rebound in the second half of the year. The company has also acknowledged uncertainty regarding typical seasonal trends due to broader macroeconomic conditions and consumer sentiment.

RxSight, Inc. is a medical technology company focused on vision enhancement for cataract surgery patients. They operate in the Healthcare sector, specifically in Healthcare Equipment & Supplies and Medical Devices. Their main product is the RxSight Light Adjustable Lens (LAL) system, which allows for post-operative adjustments to the intraocular lens using ultraviolet light.

RxSight, Inc. is headquartered in Aliso Viejo, California, and primarily operates in the United States. The company has also obtained CE marking in Europe and regulatory approval in Australia, indicating plans for global expansion.

RxSight's brand reputation, particularly concerning its Light Adjustable Lens (LAL) technology, has seen a shift in the past year. Surgeon sentiment has become more mixed, attributed to post lock-in changes, an increasing number of dissatisfied patients, surgeon dissatisfaction with the LAL+ product, and issues with the Light Delivery Device (LDD). A securities class action lawsuit alleging misleading statements about product demand has also likely impacted the company's reputation.

RxSight, Inc. has a diverse ownership structure. Institutional shareholders hold a significant portion, approximately 88.88%, with major holders including BlackRock, Inc. and Vanguard Group Inc. Insiders own about 30.93% of the company, with Ra Capital Management LP being the largest individual shareholder. The general public holds an estimated 11% stake.